electroCore
electroCore is a commercial-stage bioelectronic medicine company developing non-invasive vagus nerve stimulation devices (gammaCore, Truvaga, TAC-STIM, Quell) for migraine, cluster headache, fibromyalgia, military performance, and consumer wellness, generating revenue through hardware sales and consumable refills across DTC e-commerce, government (VA/DoD), and international distributor channels.
- Company typePublic
- Founded2005
- HeadquartersRockaway, United States
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What electroCore does
electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage bioelectronic medicine company founded in 2005 and headquartered in Rockaway, New Jersey. The company develops and commercializes non-invasive vagus nerve stimulation (nVNS) therapies delivered through proprietary handheld devices. Its core technology platform generates a patented electrical signal that stimulates the vagus nerve through the skin without implants or surgery, modulating autonomic functions including neurotransmitter levels, inflammation, and metabolism. electroCore's commercial portfolio spans prescription medical devices (gammaCore and gammaCore Sapphire for acute migraine, preventive migraine, episodic cluster headache, hemicrania continua, and paroxysmal hemicrania), consumer wellness products (Truvaga and Truvaga Plus for stress and sleep management), military applications (TAC-STIM for performance and resilience), and, following the December 2024 acquisition of NeuroMetrix, the Quell wearable neuromodulation platform for fibromyalgia and diabetic nerve pain. The company holds 200+ patents and patent applications, multiple FDA clearances spanning distinct indications, CE mark, TGA, and Health Canada approvals, and an FDA Breakthrough Device Designation for PTSD (granted January 2022).
electroCore generates revenue through a combination of upfront device sales and recurring consumable refills required for ongoing therapy, with a price-on-inquiry or direct-purchase model via company websites. Go-to-market is multi-channel: direct-to-consumer e-commerce through gammacore.com and truvaga.com; a dedicated government sales channel procuring into the Veterans Affairs and Department of Defense healthcare systems for migraine, cluster headache, and TAC-STIM deployments; and authorized distributor partnerships covering the UK, EU, Canada, Australia, New Zealand, Saudi Arabia, and UAE. Revenue reached $32.0 million in full-year 2025 with 40% year-over-year growth in Q1 2026 ($9.6 million), reflecting both organic momentum and the NeuroMetrix contribution following the May 2025 merger close. The customer base spans patients with headache and neurological disorders seeking drug-free alternatives, government healthcare systems procuring non-opioid pain management, and health-conscious consumers in the wellness channel. The company is publicly listed on the Nasdaq Global Select Market since June 2018 and maintains wholly-owned subsidiaries in the UK (electroCore UK Ltd) and Germany (electroCore Germany GmbH).
The business operates with an improving but still negative EBITDA profile ($-12.7 million in 2025 versus $-22.3 million in 2022), reflecting continued reinvestment in commercial scaling, post-merger integration costs, and clinical evidence generation including the May 2026 JAMA Network Open publication on Quell in fibromyalgia. Recent strategic moves include the NeuroMetrix merger (portfolio expansion into chronic pain), $9.3 million in 2024 public-offering proceeds to fund sales and marketing, and a March 2026 leadership transition with CEO Dan Goldberger retiring, Joshua Lev appointed Interim President, and Michael Fox joining as COO effective April 2026.
electroCore firmographics
Firmographics- Name
- electroCore
- Legal name
- electroCore, Inc.
- Website
- https://electrocore.com
- Company type
- Public
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- electroCore is a commercial-stage bioelectronic medicine company developing non-invasive vagus nerve stimulation devices (gammaCore, Truvaga, TAC-STIM, Quell) for migraine, cluster headache, fibromyalgia, military performance, and consumer wellness, generating revenue through hardware sales and consumable refills across DTC e-commerce, government (VA/DoD), and international distributor channels.
- Ownership category
- akta.pro rank
electroCore industry classification
Industry- Product category
- Neuromodulation Medical Devices
- NAICS
- Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables) (HLAHACAE)
- akta.pro secondary industries
- Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices) (CRACAQAL), Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices) (CRACAQAK)
Keywords
Where electroCore is headquartered
LocationHeadquarters
- HQ city
- Rockaway
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
electroCore business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Marketing or Sales, Technology or R&D, Operations, Supply Chain
Revenue model
- gammaCore Device Sales: Sale of the gammaCore Sapphire handheld device to patients, healthcare providers, and government health systems (VA/DoD). Device sales represent the primary upfront revenue component, with the device requiring ongoing consumable refill purchases for ongoing therapy.
- gammaCore Refills / Consumables: Ongoing sale of refill cartridges or consumable components required for continued use of the gammaCore device, creating a recurring revenue stream from the existing patient base.
- Truvaga Consumer Wellness Sales: Sale of Truvaga and Truvaga Plus wellness devices and refills directly to consumers for stress and sleep management applications, sold through the Truvaga e-commerce channel.
- Quell Chronic Pain Device Sales: Following the NeuroMetrix acquisition, Quell device and consumable sales contribute to the combined revenue stream, targeting fibromyalgia and diabetic nerve pain indications.
Go-to-market motion3 records
Distribution channels6 records
Marketing channels4 records
electroCore product offering
Product offeringCore offering
electroCore develops and commercializes non-invasive vagus nerve stimulation (nVNS) medical devices, including the prescription gammaCore Sapphire for migraine and cluster headache treatment, the over-the-counter Truvaga wellness device for stress and sleep, the TAC-STIM military performance device, and the Quell Fibromyalgia wearable neuromodulation platform acquired via the NeuroMetrix merger. The company generates revenue through device sales combined with recurring consumable refills across consumer, government healthcare (VA/DoD), and international distributor channels.
Product overview
electroCore is a commercial-stage bioelectronic medicine and wellness company offering a portfolio of non-invasive vagus nerve stimulation (nVNS) products. The core technology platform centers on gammaCore, an FDA-cleared prescription medical device for treating migraine, cluster headache, hemicrania continua, and paroxysmal hemicrania. The product line spans prescription therapeutic devices (gammaCore and gammaCore Sapphire), consumer wellness products (Truvaga and Truvaga Plus for stress/sleep), and military applications (TAC-STIM for performance). Following the May 2025 acquisition of NeuroMetrix, the portfolio expanded to include Quell Fibromyalgia, the first and only FDA-authorized wearable neuromodulation device specifically indicated for fibromyalgia pain. All products share the proprietary nVNS technology that stimulates the vagus nerve non-invasively to modulate autonomic functions.
Differentiator
Problem solved
Functional benefit
Brands
- gammaCore: Primary prescription medical device product line - non-invasive vagus nerve stimulator for migraine and cluster headache treatment
- gammaCore Sapphire
- Truvaga
- Truvaga Plus
- TAC-STIM
- Quell Fibromyalgia
- Quell Relief
Products and services
- gammaCore FDA-cleared non-invasive vagus nerve stimulator (nVNS) for acute and preventive treatment of migraine headache in adolescents (12+) and adults, acute treatment of episodic cluster headache, and adjunctive preventive treatment of cluster headache, hemicrania continua, and paroxysmal hemicrania.
- gammaCore Sapphire Reusable version of the gammaCore nVNS device featuring improved design for multiple uses, environmentally friendly construction to reduce waste, and the underlying delivery platform for multiple FDA-cleared indications.
- Truvaga Over-the-counter consumer wellness device using nVNS technology to help users feel calmer, think clearer, and sleep better through natural vagus nerve stimulation.
- Truvaga Plus Enhanced Truvaga wellness device with companion mobile software application providing guided sessions and usage tracking for stress management and sleep improvement.
- TAC-STIM Portable vagus nerve stimulation device designed specifically for military use, providing performance enhancement, resilience improvement, and accelerated learning during high-stress training environments.
- Quell Fibromyalgia FDA-authorized wearable neuromodulation device for fibromyalgia pain reduction in adults with high pain sensitivity; first and only non-drug, FDA-cleared device indicated for fibromyalgia, acquired via the NeuroMetrix acquisition.
Companies that use electroCore
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles3 records
electroCore technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
electroCore partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered core and minor.
- NeuroMetrix, Inc.coreelectroCore completed a merger with NeuroMetrix, Inc. in May 2025 for an undisclosed sum, making NeuroMetrix a wholly-owned subsidiary. This transformative combination created the only company exclusively focused on non-invasive neuromodulation with multiple commercial products. The merger brought together electroCore's gammaCore and Truvaga franchises with NeuroMetrix's Quell platform (FDA-cleared for fibromyalgia and diabetic nerve pain), significantly expanding electroCore's therapeutic footprint and combined Q1 2026 revenue to $9.6 million.
- Medistar (Australia / New Zealand)minorAuthorized distributor for electroCore products covering Australia and New Zealand, supporting commercialization of TGA-cleared gammaCore and related devices in the APAC region.
- Silvert Medical (Belgium, Netherlands, Luxembourg, France)minorAuthorized distributor covering Belgium, Netherlands, Luxembourg, and France, enabling CE-marked product commercialization across these European markets.
- Medexsol (Saudi Arabia)minorAuthorized distributor for electroCore products in Saudi Arabia, enabling market entry in the Middle East region.
- Cyrus Medical (UAE)minorAuthorized distributor for electroCore products in the United Arab Emirates, supporting regional commercialization in the Gulf Cooperation Council (GCC) market.
- UK / EU Authorized DistributorsminorRegional authorized distributor network covering the United Kingdom and European Union markets, enabling local commercialization of CE-marked electroCore and Truvaga products.
- Canada Authorized DistributionminorAuthorized distribution presence in Canada for Health Canada-cleared electroCore products, supporting the North American commercial footprint outside the direct government sales channel.
Scale indicators6 records
Recent moves7 records
Expansion highlights7 records
electroCore competitors and assessment
Company assessmentEmerging players
- Inspire Medical Systems: Inspire Medical Systems markets an FDA-approved implantable hypoglossal nerve stimulation device for obstructive sleep apnea. Inspire shares electroCore's neurostimulation platform thesis and adjacent patient populations (including sleep disorders where Truvaga also competes), but operates as an emerging surgical implant player rather than a non-invasive device company.
- NeuroPace: NeuroPace markets the RNS System, an FDA-approved responsive neurostimulation device for drug-resistant epilepsy that monitors and responds to brain activity. NeuroPace shares electroCore's neural stimulation thesis and focus on neurological disorders but operates in implantable, responsive brain stimulation rather than non-invasive vagus nerve stimulation.
- Saluda Medical: Saluda Medical develops the Evoke closed-loop spinal cord stimulation system for chronic pain, with FDA approval and ongoing expansion into additional neurostimulation indications. Saluda represents an emerging neuromodulation competitor in adjacent pain indications, sharing the bioelectronic medicine thesis with electroCore but pursuing implantable rather than non-invasive delivery.
- Cala Health: Cala Health develops wearable transcutaneous afferent patterned stimulation (TAPS) therapy devices, including FDA-cleared products for essential tremor and Parkinson's disease tremor. Cala shares electroCore's wearable, non-invasive peripheral nerve stimulation approach but focuses on movement disorders rather than headache and chronic pain indications.
Broad incumbents
- Abbott: Abbott's Neuromodulation business offers FDA-approved devices for chronic pain, movement disorders, and other conditions through spinal cord stimulation and deep brain stimulation platforms. As a broad incumbent, Abbott represents a much larger neuromodulation competitor with the resources to enter adjacent indications, though currently focused on implantable rather than non-invasive approaches.
- LivaNova: LivaNova markets the only FDA-approved implantable vagus nerve stimulation (VNS Therapy) system for drug-resistant epilepsy and treatment-resistant depression, sharing electroCore's vagus nerve stimulation mechanism but with an invasive surgical approach. As a broad incumbent in neuromodulation, LivaNova competes in adjacent patient populations and represents the most direct mechanistic alternative (VNS) albeit at a different invasiveness profile.
- Medtronic: Medtronic operates one of the broadest neuromodulation portfolios globally, including deep brain stimulation (DBS), spinal cord stimulation (SCS), and implantable VNS for epilepsy. As a broad incumbent, Medtronic overlaps with electroCore in the vagus nerve stimulation mechanism but competes primarily in invasive, surgical neuromodulation across multiple therapeutic areas.
Direct peers
- Cefaly: Cefaly produces a non-invasive trigeminal nerve stimulation (TNS) device FDA-cleared for migraine prevention and acute treatment, directly competing with gammaCore on the same headache indications, the same non-invasive external neurostimulation modality, and the same prescription/DTC channels. Both companies target patients seeking drug-free alternatives in the headache medicine market.
- eNeura: eNeura markets the SAVI Dual single-pulse transcranial magnetic stimulation (sTMS) device FDA-cleared for acute and preventive migraine, competing with gammaCore on the same headache indications with a different but still non-invasive external stimulation modality. Both companies address the prescription neuromodulation segment of the headache treatment market.
- Theranica Bioelectronics: Theranica's Nerivio is a wearable, app-controlled non-invasive neuromodulation device FDA-cleared for acute and preventive migraine, directly competing with gammaCore in the same patient population, same modality (external electrical stimulation), and same distribution channels including prescription and DTC. Both companies pursue the drug-free migraine treatment thesis with connected wearable hardware.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
electroCore social profiles
Digital presenceelectroCore compliance and trust
Trust signalCompliance3 records
electroCore financial estimates
Financial estimateRevenue estimate
Valuation estimate
electroCore leadership team
Management profileNumber of profiles
Profiles13 records
electroCore subsidiaries and ownership
Company hierarchySubsidiaries3 records
electroCore funding detail
Funding detailFunding overview
Funding rounds12 records
Investors7 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
electroCore M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about electroCore
What does electroCore do?
electroCore develops and commercializes non-invasive vagus nerve stimulation (nVNS) medical devices, including the prescription gammaCore Sapphire for migraine and cluster headache treatment, the over-the-counter Truvaga wellness device for stress and sleep, the TAC-STIM military performance device, and the Quell Fibromyalgia wearable neuromodulation platform acquired via the NeuroMetrix merger. The company generates revenue through device sales combined with recurring consumable refills across consumer, government healthcare (VA/DoD), and international distributor channels.
Is electroCore a public or private company?
electroCore is a public company. It is classified as public and is currently operating.
When was electroCore founded?
electroCore was founded in 2005. It employs 51 to 100 people.
Where is electroCore based?
electroCore is headquartered in Rockaway, United States, in the North America region.
How does electroCore make money?
Four revenue lines are on record. gammaCore Device Sales are the primary driver. The others are gammaCore Refills / Consumables, truvaga Consumer Wellness Sales and quell Chronic Pain Device Sales.
Who are electroCore's main competitors?
Emerging players on record are Inspire Medical Systems, NeuroPace, Saluda Medical and Cala Health. Broad incumbents are Abbott, LivaNova and Medtronic. Direct peers are Cefaly, eNeura and Theranica Bioelectronics.
Does electroCore have an API?
No public API is recorded for electroCore.
What industry is electroCore in?
electroCore's product category is Neuromodulation Medical Devices. Its primary akta.pro industry code is HLAHACAE, Neurological Monitoring (EEG, Seizure/Sleep/Neuro Wearables), with a secondary code of CRACAQAL, Mental Wellness & Stress Management Devices (Biofeedback, Meditation/Neurostimulation Devices). Its NAICS code is 334510 and its SIC code is 3845.